Details of the Drug Reposition

General Information of This Drug (ID: DMK6QBZ)

Drug Name
OMS721   DMK6QBZ

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Atypical hemolytic uremic syndrome DIS6FUDJ 3A10.Y Phase 3 [1]
------------------------------------------------------------------------------------
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Thrombotic microangiopathy DISLZ0VW 3B65 Phase 2 [2]
Lupus DISOKJWA 4A40 Phase 2 [3]
Glomerulonephritis DISPZIQ3 5D00.Y Phase 2 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03205995) Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome (aHUS). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)